Clinical reviewer: Dr. Sarah Boss, MD

COGNIFUL, part of THE BALANCE GROUP, publishes this guide. The selected UK routes and Mallorca option have different roles. Their inclusion is not an independent ranking, and it does not mean that community services, private hospitals and residential accommodation provide the same care.

The NHS describes a GP or local drug treatment service as routes to help, with treatment tailored to the person’s circumstances. For prescribed medication, ask specifically who manages that medicine locally and whether specialist review is needed. A general addiction-service listing does not establish the exact arrangements for every prescribed sedative or medical complication. [5]

Explain actual use, prescriptions, alcohol, recent changes, previous withdrawal and any overdose or psychiatric crisis. If a substance’s contents are uncertain, say so. An assessment should identify what is known and what needs further medical investigation. With consent, existing records and prescribers can help establish a reliable starting point.

Ask whether the immediate need is medical withdrawal management, treatment of ongoing harmful use, an urgent health problem or review of a prescribed medicine. These needs can overlap, but they are not interchangeable. The appropriate setting follows that assessment; a preferred length of leave from work should not determine the medical recommendation.

Priory Hospital Roehampton publishes medically assisted detox and inpatient addiction treatment, together with day and outpatient options. Confirm which actual program accepts the substance and medical history involved, who evaluates risk and which needs require another hospital. The provider’s broad service description should lead to a specific admission proposal. [6]

A GP or local treatment team may already know the person’s history and can help establish continuity. Ask how any private admission will communicate with that team and whether the receiving clinician has accepted the plan. Private payment does not itself create a handover, while a community route should not be dismissed before its clinical suitability is understood. [5]

The COGNIFUL row is a possible later step in Spain. It should not be read as a replacement for a UK medical detox unit or as confirmation that a prescription can be continued abroad. Suitability and prescribing responsibilities require explicit agreement before travel. [4]

The CDC advises against detoxification alone for opioid use disorder and recommends offering or arranging medication treatment. This is a clinical principle to discuss with a UK provider; the exact service and prescribing arrangements must be determined locally. Ask how the recommended ongoing treatment continues through admission and discharge. [1]

A program should not frame the end of withdrawal as the end of opioid care. Clarify which professional accepts responsibility next, what appointments are confirmed and what happens if the person moves between a UK service and a residence abroad. Necessary medical treatment should not become an unresolved administrative question at the point of transfer.

The CDC also includes overdose education and naloxone within opioid use disorder care. Ask the responsible team how that applies to the person and household. If prescription pain medication is involved, identify how the original pain condition is assessed and managed alongside any harmful pattern of use. The individual should not have to choose which problem may be discussed. [1]

The joint benzodiazepine guideline separates physical dependence from substance use disorder. Someone taking medication as prescribed may need a careful medical review without meeting criteria for addiction. Conversely, harmful use should be assessed even when a prescription originally had a legitimate purpose. The service should explain its conclusions in language the person understands. [2]

Abruptly stopping or rapidly reducing benzodiazepines can cause serious withdrawal, including seizures. Combining them with alcohol or opioids can add serious risks. Do not change medication independently before a consultation, private admission or flight. Ask the responsible clinician what setting and oversight the actual situation requires. [8]

A prolonged clinician-led process may continue beyond the available residential stay. Ask the UK prescriber and any receiving provider how they will coordinate if that is the case. The appointment after discharge is part of the plan, not a detail to leave until the person returns. A fixed package should not force the pace of medical change. [2]

ASAM and AAAP guidance addresses stimulant intoxication and withdrawal, including medical and psychiatric complications. Ask which symptoms the proposed detox service assesses and when acute medical or psychiatric care takes priority. Expertise in alcohol or sedative withdrawal does not establish every capability needed for a different substance. [3]

Where multiple drugs are involved, one clinician or coordinated team should hold the complete history. Include substances used occasionally and prescribed medicines that seem unrelated to the main concern. The team should explain how conflicting instructions are resolved; the person should not be expected to reconcile several medical plans without professional help.

An assessment should also consider the original reason for prescribed treatment and any current mental health needs. The provider should say what it can treat directly and where it needs external specialists. A broad claim to address co-occurring conditions does not mean a residential setting can manage acute psychiatric instability. [4]

A residential stay abroad should have a defined therapeutic purpose after medical needs are addressed. Ask what work is proposed, why that setting may fit and how it connects to care at home. Distance from familiar pressures may be a preference, but it does not by itself establish clinical suitability or remove the need for ongoing prescribing.

Before traveling, confirm the relevant medication, transport and entry requirements with clinicians and appropriate authorities. The UK discharge plan should be shared with and accepted by the next service. Do not assume that a UK prescription, a named medication or a previous medical recommendation can simply be transferred unchanged to another country.

The return pathway deserves the same attention as arrival. Identify a UK professional who has agreed to the next appointment and understands any continuing medical treatment. Discuss what information will be shared and obtain the required consent. A family member can help organize practicalities without becoming the sole link between clinicians.

COGNIFUL’s assessment considers substance use, withdrawal risk, current health and suitability for the shared Mallorca residence. COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. If another medical setting is required first, that requirement should shape the sequence before residential arrangements are finalized. [9] [4] The medical plan, prescribing responsibilities and any additional specialist support are confirmed individually.

For a suitable person after stabilization, the residential plan may focus on understanding the pattern of use, improving coping, addressing family relationships and preparing for ordinary responsibilities. Ask for the proposed clinical work and the professionals involved. Completing a detox admission elsewhere is useful history, but does not automatically make every residential program appropriate.

COGNIFUL accepts a maximum of four clients at a time, each with a private suite. Clinical and bodywork sessions are individual. The residence, chef, personal manager, other holistic sessions, activities and excursions are shared. These details describe daily life and privacy; they do not establish a fixed staffing ratio or the continuous medical resources of a hospital. [7]

COGNIFUL Premier and Premier Plus both include assessment, a personal plan and continuing-care planning. Plus includes additional individual therapeutic work, family and transition work, and three months of aftercare. Follow-up for the base program is agreed individually. Typical residential stays are four to twelve weeks, subject to individual review. [7] View program fees

COGNIFUL’s published fees and stay range concern residential care rather than a UK or Spanish detox package. Request a written proposal confirming duration, total cost, inclusions and any external medical arrangements. The service is generally self-pay without direct insurer billing or a guarantee of reimbursement. A private insurer’s decision about any separate UK service should be verified with the insurer and provider concerned. [7]

Ask what COGNIFUL follow-up will actually include after returning to the UK and which responsibilities remain with local clinicians. The individual agreement determines support under the chosen program. No unrestricted cross-border prescribing or emergency response should be assumed. The handover should preserve necessary treatment and give the person a usable next step. [10] [4]

• Which assessed condition requires detox, and what setting is recommended?
• Who can manage the particular substance and any co-occurring health needs?
• What ongoing treatment is confirmed after the medical phase?
• Have the UK and overseas clinicians accepted the same transfer plan?
• What happens to timing and costs if more medical care is required?

The answer may involve an appropriate UK pathway throughout, or UK medical care followed by a suitable overseas residence. A coherent plan explains the reason for each stage. It should not require the person to fit several disconnected bookings around an unresolved medical need.

Where can a UK resident start asking for help?

A GP or local drug treatment service can provide an entry route. Ask specifically about the substance or prescribed medicine involved and the appropriate specialist assessment. [5]

Is detox enough for opioid use disorder?

No. The CDC advises against detoxification alone and recommends medication treatment. Confirm the ongoing clinical arrangement before leaving the medical service. [1]

Must every benzodiazepine-dependent person enter rehab?

No. Dependence is distinct from addiction, and the guideline recognizes outpatient care for many people. The medical history and risks determine the appropriate pathway. [2]

Is COGNIFUL a UK drug-detox provider?

No UK location is established; COGNIFUL is in Mallorca, Spain. COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. Suitability for a later residential phase requires review. [4] [7]

COGNIFUL admissions can discuss the information needed for a suitable Mallorca stay after required medical care. Share the UK treatment plan and continuing needs. Suspected overdose, breathing difficulty, a seizure or immediate danger requires urgent local help, not travel to a residential program. [7] [8]

1. Opioid use disorder: treating — Centers for Disease Control and Prevention.
2. Joint Clinical Practice Guideline on Benzodiazepine Tapering — American Society of Addiction Medicine and partner societies.
3. Clinical Practice Guideline on the Management of Stimulant Use Disorder — American Society of Addiction Medicine and American Academy of Addiction Psychiatry.
4. Clinical scope, suitability and care coordination — COGNIFUL.
5. Drug addiction: getting help — NHS.
6. Priory Hospital Roehampton — Priory.
7. COGNIFUL programs, fees, admissions and suitability — COGNIFUL.
8. Benzodiazepine safety communication — US Food and Drug Administration.
9. Prescription medication concerns and residential treatment — COGNIFUL.
10. Reintegration and continuing care — COGNIFUL.

Primary clinical and provider pages accessed October 18, 2026. Individual services, admission and fees should be confirmed directly.